StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
William Blair on Sarepta Therapeutics (SRPT): 'we continue to view the stock’s near-term upside potential as limited'
July 18, 2025 8:58 AM
William Blair analyst Sami Corwin reiterated a Market Perform rating on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "Stock thoughts ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)
July 21, 2025 6:55 AM
BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
July 21, 2025 6:03 AM
Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty'
July 18, 2025 2:19 PM
Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'
July 18, 2025 9:42 AM
Morgan Stanley Reiterates Equalweight Rating on Sarepta Therapeutics (SRPT)
July 18, 2025 9:33 AM
Goldman Sachs Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
July 18, 2025 8:59 AM
Leerink Partners Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
July 18, 2025 8:55 AM
Sarepta Therapeutics (SRPT) PT Lowered to $41 at Oppenheimer
July 18, 2025 8:34 AM
Sarepta shares tumble after report of patient death in early-stage trial
July 18, 2025 6:54 AM
Sarepta Therapeutics (SRPT) PT Raised to $28 at TD Cowen
July 18, 2025 5:44 AM
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
July 17, 2025 4:02 PM
Sarepta Therapeutics (SRPT) PT Lowered to $23 at RBC Capital
July 17, 2025 10:28 AM
Sarepta Therapeutics (SRPT) PT Lowered to $32 at Piper Sandler
July 17, 2025 10:24 AM
Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
July 17, 2025 8:33 AM
Needham Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
July 17, 2025 7:11 AM
Sarepta Therapeutics (SRPT) PT Raised to $35 at Baird
July 17, 2025 7:09 AM
Sarepta Therapeutics (SRPT) PT Lowered to $65 at Wells Fargo
July 17, 2025 7:07 AM
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
July 17, 2025 6:48 AM
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
July 17, 2025 6:42 AM
Sarepta Therapeutics (SRPT) PT Raised to $32 at Barclays
July 17, 2025 4:29 AM
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
July 16, 2025 4:58 PM
After-hours movers: United Airlines, Sarepta Therapeutic, MP Materials
July 16, 2025 4:54 PM
Form 8-K Sarepta Therapeutics, For: Jul 14
July 16, 2025 4:11 PM
Sarepta cuts 36% of workforce, expects $400M in annual savings
July 16, 2025 4:01 PM
